Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Triple-negative breast cancer: promising prognostic biomarkers currently in development99
TIM-3 pathway dysregulation and targeting in cancer58
TKIs in combination with immunotherapy for hepatocellular carcinoma54
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis46
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy43
Optimal treatment in locally advanced cervical cancer32
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer31
Pediatric relapsed acute myeloid leukemia: a systematic review28
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies28
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies27
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy26
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis24
Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis23
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer23
The role of the microbiome in drug resistance in gastrointestinal cancers23
Pembrolizumab for advanced cervical cancer: safety and efficacy20
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review20
Radiomics features as predictive and prognostic biomarkers in NSCLC20
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma19
0.17413878440857